Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer (clinicaltrials.gov) - Oct 23, 2026 - P2 | N=100 | Recruiting | Sponsor: Solstice Oncology, Inc. | Not yet recruiting ➔ Recruiting
Enrollment open • pMMR • Colon Adenocarcinoma • Colon Cancer • Colorectal Cancer • Oncology • Solid Tumor
|